Hypericum-Extrakt

  • A. Singer
  • W. E. Müller
Chapter

Zusammenfassung

Extrakte der Arzneipflanze Hypericum perforatum werden in vielen Ländern immer häufiger für die Behandlung depressiver Erkrankungen verwendet. Arzneimittel auf der Basis von Zubereitungen aus Hypericum perforatum (Johanniskraut) werden als Phytopharmaka bezeichnet. Deren Wirkstoff ist in der Regel keine chemisch definierte Einzelsubstanz, sondern ein Gemisch aus einer Reihe von sekundären Naturstoffen.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur

  1. BAKER G B, GREENSHAW A J (1989) Effects of longterm administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell Mol Neurobiol 9: 1–44PubMedGoogle Scholar
  2. BAUREITHEL KM, BUTER KB, ENGESSER A, BURKARD W, SCHAFFNER W (1997) Inhibition of benzodiazepine binding in vitro by Amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 72: 153–157PubMedGoogle Scholar
  3. BHATTACHARYA SK, CHAKRABARTI A, CHATTERJEE SS(1998) Activity profiles of two hyperforin-con-taining Hypericum extracts in behavioral models. Pharmacopsychiatry 31 [Suppl I]: 22–29PubMedGoogle Scholar
  4. BIBER A, FISCHER H, RÖMER A, CHATTERJEE SS (1998) Oral bioavailability of Hyperforin from Hypericum extract in rats and human volunteers. Pharmacopsychiatry 31 [Suppl 1]: 36–43PubMedGoogle Scholar
  5. BLADT S, WAGNER H (1994) Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol 7 [Suppl 1]: 57–59Google Scholar
  6. BROCKMOLLER J, REUM T, BAUER S, KERB R, HÜBNER W-D, ROOTS I (1997) Hyperirin and pseudohy-pericin: pharmacokinetics and effects on pho-tosensitivity in humans. Pharmacopsychiatry 30 [Suppl 2]: 94–101PubMedGoogle Scholar
  7. BLITTERWECK V, WALL A, LIEFLANDER-WUULF U, WIN-TERHOFF H, NAHRSTEDT A (1997) Effects of the total extract and fractions of Hypericum perforatum in animal assays of antidepressant activity. Pharmacopsychiatry 30 [Suppl 2]: 117–125Google Scholar
  8. BUTTERWECK V, PETEREIT E, WINTERHOFE H, NAHRSTEDT (1998) Solubilized Hyperirin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 64: 291–294PubMedGoogle Scholar
  9. BUTTERWECK V, JÜRGENHEMK G, NAHRSTEDT A, WIN-TERHOFF H (2000) Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 66:3–6PubMedGoogle Scholar
  10. CHATTERJEE SS, NÖLDNER M, KOCH E, ERDELMEIER C(1998a) Antidepressant activity of Hypericum perforatum and Hyperforin: the neglected possibility. Pharmacopsychiatry 31 [Suppl 1]: 7–15PubMedGoogle Scholar
  11. CHATTERJEE SS, BHATrACHARYA SK, WONNEMANN M, SINGER A, MOLLER WE (1998b) Hyperforin as a possible antidepressant component of Hypericum extract. Life Sci 63: 499–510PubMedGoogle Scholar
  12. CHATTERJEE SS, FILIPPOV V, LISHKO P, MAxIMYUK O, NÖLDNER M, KRISHTAL O (1999) Hyperforin at-tenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Sci 65: 2395–2405PubMedGoogle Scholar
  13. CHATTTRJEE SS, BIBER A, WEIBEZAHN C (2001) Stim-ulation of glutamate, asparate and gammaaminobutyric acid release from synaptosomes by Hyperforin. Pharmacopsychiatry 34 [Suppl]: 11–19Google Scholar
  14. Corr JM (1997) In vitro recepror binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30 [Suppl 2]: 108–113Google Scholar
  15. DE VRY J, MAUREL S, SCHREIBER R, DE BEUN R, JENTZSCH KR (1998) Comparison of the effects of Hypericum extracts Imipramine and Fluoxetine in rat models of depression and alcoholism. Eur Neuropsychopharmacol 8: 162Google Scholar
  16. DEMISCH L, HOLZL J, GOLLNIK B, KACZMARCZYK P(1989) Identification of selective MAO-type-Ainhibitors in Hypericum perforatum L. Pharmacopsychiatry 22: 194Google Scholar
  17. DIMPFEL W, SCHOMBERT L (1997) Central action of Hyperici herba cum flore extractum siccum in freely moving rats. Eur J Med Res 2: 491–496PubMedGoogle Scholar
  18. DIMPFEL W, SCHOBER F, MANTEL M (1998) Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John’s Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-StereoEEG). Pharmacopsychiatry 31 [Suppl 1]: 30–35PubMedGoogle Scholar
  19. Fox E, MURPHY R F, McCuLLY CL, ADAMSON PC (2001) Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 47: 41–44PubMedGoogle Scholar
  20. FRANKLIN M, COWEN PJ (2001) Researching the antidepressant actions of Hypericum perfora-turn (St. John’s Wort) in animals and man. Pharmacopsychiatry 34 [Suppl]: 29–37Google Scholar
  21. GIESE A (1980) Hypericism. Photochem Photobiol Rev 5: 229–255Google Scholar
  22. GOBBI M, VALLE F D, CIAPPARELLE C et al. (1999) Hypericum perforatum L Extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 360: 262–269PubMedGoogle Scholar
  23. GREESON J M, SANFORD B, MONTI D (2001) St. John’s Wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 153: 402–414PubMedGoogle Scholar
  24. KAEHLER S T, SINNER C, CHATTERJEE S S, PHILIPPU A(1999) Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci Lett 262: 199–202PubMedGoogle Scholar
  25. KRISHTAL O, LOZOVAYA N, FISUNOV A, TSINTSADZE T, PANKRATOV Y, KOPANITSA M, CHATTERJEE SS(2001) Modulation of ion channels in rat neu-rons by the constituents of Hypericum Perfora-turn. Pharmacopsychiatry 34 [Suppl 1]: S74–S82PubMedGoogle Scholar
  26. LAAKMANN G, SCHÜLE C, BAGHAI T, KIESER M (1998) St. John’s Wort in mild to moderate depression: the relevance of Hyperforin for the clinical efficacy. Pharmacopsychiatry 31 [Suppl 1]: 54–59PubMedGoogle Scholar
  27. LEONARD BE (1993) Comparative pharmacology of new antidepressants. J Clin Psychiatry 54 [Suppl]: 6–15Google Scholar
  28. LEONARD BE (1995) Mechanisms of action of anti-depressants. CNS Drugs 4 [Suppl]: 1–12Google Scholar
  29. LINDE K, RAMIREZ G, MULROW C D, PAULS A, WEIDENHAMMER W, MELCHART D (1996) St. John’s wort for depression – an overview and meta-analysis of randomised clinical trials. BMJ 313:253–258PubMedGoogle Scholar
  30. MISANE I, OGREN SO (2001) Effects of hypericum perforatum (St. John’s wort) on passiv avoidance in the rat: evaluation of potential neurochemical mechanisms underlying its antidepressant activity. Pharmacopsychiatry 34 [Suppl 1]: 89–97Google Scholar
  31. MÜLLER WE, ROTH M, SCHAFER C, HAFNER U (1997) Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 30 [Suppl 2]: 102–108PubMedGoogle Scholar
  32. MÜLLER WE, SINGER A, WONNEMANN M, HAFNER U, Row M, SCHAFER C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituents of Hyperforin extract. Pharmacopsychiatry 31 [Suppl 1]: 16–21PubMedGoogle Scholar
  33. MÜLLER WE, SINGER A, WONNEMANN M (1999) Jo-hanniskraut – vom Nerventee zum modernen Antidepressivum. Dtsch Apoth Ztg 139: 49–58Google Scholar
  34. MÜLLER WE, SINGER A, WONNEMANN M (2000) Zum Wirkungsmechanismus von Johanniskrautextrakt. Praxis 89: 2111–2121PubMedGoogle Scholar
  35. MÜLLER WE, SINGER A, WONNEMANN M (2001) Hy-perfoin – antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 34 [Suppl]: 98–102Google Scholar
  36. NATHAN P (1999) The experimental and clinical pharmacology of St. John’s Wort (Hypericum perforatum L.). Mol Psychiatry 4: 333–338PubMedGoogle Scholar
  37. NATHAN P (2001) Hypericum perforatum (St. John’s Wort): a non selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 15: 47–54PubMedGoogle Scholar
  38. OSTROWSI E (1988) Untersuchungen zur Analytik 14C-Markierung and Pharmakokinetik phenolischer Inhaltsstoffe von Hypericum perfora-turn L. Dissertation, Philipps-Universität MarburgGoogle Scholar
  39. PHILIPPU A (2001) In vivo neurotransmitter release in the locus coeruleus – effects of hyperforin, inescapable shock and fear. Pharmacopsychiatry 34 [Suppl]: 111–115Google Scholar
  40. Rout M, SCHAFER C, MÜLLER WE (1995) Effect of hypericum extract (Li160) on neurotransmitter receptor binding and synaptosomal uptake systems. Pharmacopsychiatry 28: 207Google Scholar
  41. SCHELLENBERG R, SAUER S, DIMPFEL W (1998) Phar-macodynamik effects of two different Hypericum extracts in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry 31 [Suppl 1]: 44–53PubMedGoogle Scholar
  42. SERDAREVIC N, ECKERT G P, MULLER W E (2001) The effects of extracts from St. John’s wort and Kava Kava on brain neurotransmitter levels in the mouse. Pharmacopsychiatry 34 [Suppl]: 134–136Google Scholar
  43. SINGER A, WONNEMANN M, MULLER WE (1999) Hy-perforin, a major antidepressant constituent of St. John’s wort, inhibits serotonin uptake by elevating free intracellular Na*.ll. J Pharmacol Exp Ther 290: 1363–1368PubMedGoogle Scholar
  44. SPARENBERG B, DEMISCH L, HÖLZL J (1993) Unter-suchung über anticlepressive Wirkstoffe von Johanniskraut. Pharm Ztg Wiss 6/138: 50–54Google Scholar
  45. STAFFELDT, B, KERB R, BROCKMÖLLER J, PLOCH M, ROOTS I (1994) Pharmacokinetics of Hypericin and Pseudohyperidin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers. J Geriat Psychiatry Neurol 7 [Suppl 1]: 47–53Google Scholar
  46. STOCK S, HÖLZL J (1991) Pharmacokinetic test of (14C-)-labelled hypericin and pseudohypericin from Hypericum perforatum and serum kinetics of Hypericin in man. 39th Annual Congress on Medicinal Plant Research. Thieme, Stuttgart, pp 61–62 (Abstract)Google Scholar
  47. SUZUKI O, KATSUMATA Y, OvA M, BLADT S, WAGNER H (1984) Inhibition of monoamine oxidase by Hypericin. Planta Med 50: 272–274PubMedGoogle Scholar
  48. TEUFEL-MAYER, J GLEIZ (1987) Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonergic 5-HT1A and 5-HT2A receptors. Pharmacopsychiatry 30 [Suppl II]: 113–116Google Scholar
  49. THIEDE H-M, WALPER A (1994) Inhibition of MAO and COMT by Hypericum extract and Hypericin. J Geriatr Psychiatry Neural 7 [Suppl 1]: 54–56Google Scholar
  50. WEISER D (1991) Pharmakokinetik von Hypericin nach oraler Einnahme des Johanniskraut-Extraktes LI 160. Nervenheilkunde 10: 318–319Google Scholar
  51. WHEATLEY D (1998) Hypericum extract. CNS Drugs 9: 431–440Google Scholar
  52. WONNEMANN M, SINGER A, MÜLLER WE (2000) Inhi-bition of synaptosomal uptake of 3H-L-gluatamate and 3H-GABA by hyperforin, a major constituent of St. John’s wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacol 23: 188–197Google Scholar
  53. WONNEMANN M, SINGER A, SIEBERT B, MÜLLER WE(2001) Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John’s wort. Pharmacopsychiatry 34 [Suppl]: 148–151Google Scholar
  54. WURGLICS M, WESTERHOFF K, KAUNZINGER A, WILKE A, BAUMEISTER A, DRESSMAN J, SCHUBERT-ZSI- LAVECZ M (2001) Batch-to-batch reproducibility of St. John’s wort preparations. Pharmacopsychiatry 34 [Suppl]: 152–156Google Scholar

Literatur

  1. ARAYA OS, FORD EJH (1981) An investigation of the type of photosensitization caused by the ingestion of St. John’s wort (Hypericum perforatum) by calves. J Comp Path 91: 135–141PubMedGoogle Scholar
  2. ARZNEIMITTELKOMMISSION DER DEUTSCHEN ÄRZTE SCHAFT (2000) Johanniskrautpräparate — Ge-fährliches Interaktionsrisiko. Dtsch Ärztebl 97: C-216Google Scholar
  3. BERGMANN R, NÚSSNER J, DEMLING J (1993) Be handlung leichter bis mittelschwerer Depres-sionen. Vergleich von Hypericum perforatum mit Amitriptylin. TW Neurol Psychiat 7: 235–240Google Scholar
  4. BOVE GM (1998) Acute neuropathy after exposure to sun in a patient treated with St. John’s wort. Lancet 352: 1121–1122PubMedGoogle Scholar
  5. BROCKMÖLLER J, REUM T, BAUER S, KERB R, HÜBNER ED, ROOTS I (1997) Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30 [Suppl]: 94–101PubMedGoogle Scholar
  6. CoRCILIUS F (1960) Stoffwechselbeeinflussung durch fluoreszierende Substanzen. Dtsch Apoth Ztg 100: 643–646Google Scholar
  7. DITZLER K, SCHOTTEN W (1992) Johanniskraut bei leichten bis mittelschweren Depressionen. Ergebnisse einer plazebo-kontrollierten Doppelblindstudie. Heilkunst 105: 3–10Google Scholar
  8. ERNST E (1999) Second thoughts about safety of St. John’s wort. Lancet 354: 1014–1015Google Scholar
  9. ERNST E, RAND JI, BARNES J, SmvINSON C (1998) Adverse effects profile of the herbal antidepressant St. John’s wort (Hypericum perforatum L.). Eur J Clin Pharmacol 54: 589–594PubMedGoogle Scholar
  10. HÄNSGFN K D, VESPER J, Ploch M (1993) Multizen-trische Doppelblindstudie zur antidepressiven Wirksamkeit des Hypericum-Extraktes LI 160. Nervenheilkunde 12: 285–289Google Scholar
  11. HALAMA P (1991) Wirksamkeit des Hypericum Extraktes LI 160 hei 50 Patienten einer psychiatrischen Fachpraxis. Nervenheilkunde 10: 305–307Google Scholar
  12. HARRER G, SOMMER H (1993) Therapie leichter/ mittelschwerer Depressionen mit Hypericum. Münch Med Wochenschr 135: 305–309Google Scholar
  13. HARRER G, SCHMIDT U, KUHN U (1991) „Alternative“ Depressionsbehandlung mit einem Hypericum-Extrakt. TW Neurol Psychiat 12: 91Google Scholar
  14. HARRER G, HOBNER W-D, PODZUWEIT H (1993) Wirksamkeit und Verträglichkeit des Hypericum-Präparates LI 160 im Vergleich zu Maprotilin. Multizentrische Doppelblindstudie mit 102 depressiven Patienten. Nervenheilkunde 12: 197–201Google Scholar
  15. HARRER G, SCHMIDT U, KUHN U, BILLER A (1999) Äquivalenzvergleich Johanniskrautextrakt LoHyp-57 versus Fluoxetin. Arzneimittelforschung/Drug Res 49: 289–296Google Scholar
  16. HERBERC KW (1994) Psychotrope Phytopharmaka im Test. Alternative zu synthetischen Psychopharmaka. Therapiewoche 44: 704–713Google Scholar
  17. HOFFMANN J, KOHL E-D (1979) Therapie von depressiven zuständen mit Hypericin. Z Allgemeinmed 55: 776–782Google Scholar
  18. HÜBNER W-D, LANDE S, PODZUWETT H (1993) Be-handlung larvierter Depressionen mit Johanniskraut. Nervenheilkunde 12: 278–280Google Scholar
  19. HYPERICUM DEPRESSION TRIAL STUDY GROUP (2002) JOHNE A, BROCKMOLLER J, BAUER S, MAURER A, LANG-Effect of Hypericum perforatum (St. John’s Wort) in major depressive disorder. A randomised controlled clinical trial. JAMA 287: 1807–1814Google Scholar
  20. HEINRICH M, ROOTS I (1999) Pharmacokinetic interaction of digoxin with an herbal extract of St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 66: 338–345Google Scholar
  21. LAAKMANN G, SCHULE C, BAGHAI T, KTFSER M (1998) St. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 [Suppl]: 1–6Google Scholar
  22. LEHRL S, WILLEMSEN A, PAPP R, WOELK H (1993) Ergebnisse von Messungen der kognitiven Leistungsfähigkeit hei Patienten unter der Therapie mit Johanniskraut-Extrakt. Nervenheilkunde 12: 281–284Google Scholar
  23. LINDE K, RANIIREZ G, MULROW CD, PAULS A, WEIDEN-HAMMER W, MELCHART D (1996) St John’s wort for depression — an overview and meta-analysis of randomised clinical trials. BMJ 313: 253–258PubMedGoogle Scholar
  24. MAURER A, JOHNE A, BAUER S, BROCKMÖLLER J, DONATH F, ROOTS I et al. (1999) Interaction of St. John’s wort extract with phenprocoumon. Eur J Clin Pharmacol 55: A22 [abstract]Google Scholar
  25. NEBEL A, SCHNEIDER BJ, BAKER RK, KROLL DJ (1999) Potential metabolic interaction between St. John’s wort and theophylline. Ann Pharmacother 33: 502PubMedGoogle Scholar
  26. OSI’ERHEIDER M, SCHMIDTKE A, BECKMANN H (1992) Behandlung depressiver Syndrome mit Hypericum (Johanniskraut) — einc placebokontrollierte Doppelblindstudie. Fortschr Neurol Psychiat 60 (Sonderheft 2): 210–211Google Scholar
  27. PISCRRELLI SC, BERNSTEIN AH, CHAUT D, ALFARO RM, FALLDON J (2000) Indinavir concentrations and St John’s wort. Lancet 355: 547–548Google Scholar
  28. POGINSKY B, WESTENDORF J, PROSNEC N, KUPPE M, MARQUARDT H (1988) Johanniskraut. Genotoxizität bedingt durch den Quercetingehalt. Dtsch Apoth Ztg 128: 1364–1366Google Scholar
  29. QUANDTJ, SCHMIDT U, SCHENK N (1993) Ambulante Behandlung leichter bis mittelschwerer depressiver Verstimmungen. Der Allgemeinarzt 2: 97–102Google Scholar
  30. REH C, LAUX P, SCHENK N (1992) Hypericum-Extrakt bei Depressionen — eine wirksame Alternative. Therapiewoche 42: 1576–1581Google Scholar
  31. ROBA CA, ANDERSON GD, KANTOR F, DRYER DA, BURSTEIN AH (1999) St. John’s wort: impact on CYP 3A4 activity. Poster, 39th Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, June 1–4Google Scholar
  32. RUSCHTTZKA F, MEIER PJ, TURINA M, LUSCHER TF, Non. G (2000) Acute heart transplant rejection due to Saint John’s wort. Lancet 355: 548–549Google Scholar
  33. SCHILLING W (1969) Gattung Hypericum unter besonderer Berücksichtigung von Hypericum perforatum L. Präp Phann 8: 125–134Google Scholar
  34. SCHIMMER O (1989) Hypericum perforatum, Johanniskraut. Therapeutikon 2: 76–81Google Scholar
  35. SCHIMMER O, HAFELE F, KRÜGER A (1988) The mu-tagenic potencies of plant extracts containing quercetin in Salmonella typhimurium TA98 and TA100. Mutat Res 206: 201–208PubMedGoogle Scholar
  36. ScttucH D, BRALKMANN F, SCIIENK N (1987) Be-handlung depressiver Zustandsbilder mit Hypericinium. Doppelblindstudie mit einem pflanzlichen Antidepressivum. Psycho 13: 440–445Google Scholar
  37. SCHMIDT U, SOMMER H (1993) Johanniskraut-Extrakt zur ambulanten Therapie der Depression. Fortschr Med 111: 339–342PubMedGoogle Scholar
  38. SCIIM EDT U, SCHENK N, SCIIVARZ I, VORBERG G (1989) Hypericum-Applikation. Zur Therapie depressiver Verstimmungen. Psycho 15: 665–671Google Scholar
  39. SCHMIDT U, HARRER G, KUHN U, BERGER-DEINERT W, LUTHER D (1993) Wirkungen von HypericumExtrakt mit Alkohol. Placebo-kontrollierte Doppelblindstudie mit 32 Probanden. Nervenheilkunde 12: 314–319Google Scholar
  40. SCHRADER E, MEIER B, BRATTSTRÖM A (1998) Hyper-icum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multiccntre study. Hum Psychopharmacol 13: 163–169Google Scholar
  41. SCHULZ V, HANSEL R (1999) Johanniskraut als Antidepressivum. In: SCHULZ V, HANSEL R (Hrsg) Rationale Phytotherapie. Springer, Berlin Heidelberg New York Tokyo, S 59–78Google Scholar
  42. STIELTON RC, KELLER MB, GELENBERG A, DUNNER DL, HIRSCHFELD R, THASE ME, RUSSELL J, LYDIARD RB, CRITS-CRISTOPH P, GALLOP R, TODD I., HELLER-STEIN D, GOODNICK P, KFITNER G, STAHL SM, HALBREICH U (2001) Effectiveness of St John’s Wort in major depression. A randomized controlled trial. JAMA 285: 1978–1986Google Scholar
  43. SOMMER H, HARRER G (1993) Placebo-kontrollierte Studie zur Wirksamkeit eines Hypericum-Präparates bei 105 Patienten mit Depressionen. Nervenheilkunde 12: 274–277Google Scholar
  44. STOCK S, HöLZL J (1991) Ist Johanniskraut photo-toxisch? Med Monatsschr Phann 14: 304–306Google Scholar
  45. UAW-NEws INTERNATIONAL (2000) Dtsch Ärztebi 97: C-624Google Scholar
  46. VOLZ HP (1997) Controlled trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry 30 [Suppl]: 1–9PubMedGoogle Scholar
  47. VOLZ HP, HÄNSEL R (1995) Hypericum (Johannis-kraut) als pflanzliches Antidepressivum. PTT 2: 61–67Google Scholar
  48. VOLZ HP, LAUX P (1999) Antidepressive Pharmakotherapie leichter bis mittelgradiger depressiver Störungen. Ein Vergleich von Johanniskrautextrakten mit Fluoxetin. PTT 6: 138–142Google Scholar
  49. VOLZ HP, LAUX P (2000) Potential treatment for subthreshold and mild depression. A cornparison between St. John’s wort extracts andlluoxetine. Compr Psychiatry 41 [Suppl1]: 133–137PubMedGoogle Scholar
  50. VOLZ HP, EBERHARDT R, GRILL G (2000) Sicherheit und Verträglichkeit des Johanniskrautextraktes D-0496 bei leichten bis mittelschweren depressiven Episoden - eine Placebo-kontrollierte Doppelblindstudie über 6 Woche. Nervenheilkunde 19: 401–404Google Scholar
  51. VORBACH E-U, HÜBNER W-D, ARNOLD K-II (1993) Wirksamkeit und Verträglichkeit des Hypericum-Extraktes LI 160 im Vergleich zu Imipramin. Randomisierte Doppelblindstudie mit 135 ambulanten Patienten. Nervenheilkunde 12: 290–296Google Scholar
  52. VORBACH E-U, ARNOI.DT KH, HÚFTNER WD (1997) Efficacy and tolerability of St. John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD10. Pharmacopsychiatry 30 [Suppl 2]: 81–85PubMedGoogle Scholar
  53. WHEATLEY D (1997) LI 160, an extract of St. John’s wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week trial. Pharmacopsychiatry 30 [Suppl 2]: 77–80PubMedGoogle Scholar
  54. WITTE B, HARRER G, KAPTAN T, PODZUWEIT H, SCHMIDT U (1995) Behandlung depressiver Verstimmungen mit einem hochkonzentrierten Hypericumpräparat. Eine multizentrische plazebokontrollierte Doppelblindstudie. Fort-sehr Med 133: 405/49–54/408Google Scholar
  55. WOELK H, BURKARD G, GRÜNWALD J (1993). Nutzen und Risikobwertung des Hypericum-Extraktes LI 160 auf der Basis einer Drug-MonitoringStudie mit 3250 Patienten. Nervenheilkunde 12: 308–313Google Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  • A. Singer
  • W. E. Müller

There are no affiliations available

Personalised recommendations